PDCD1 and B-cell non-Hodgkin lymphoma: However, minimal response with no meaningful durability has also been reported in two relapsed, refractory (R/R) B-cell non-Hodgkin lymphoma patients receiving the combination therapy of bispecific CAR T cells and PD-1 inhibitors (221).